Carlyle to buy 5% stake in Shenzhen Salubris Pharma for $260m

Photo: Reuters

Carlyle Group agreed to invest 1.78 billion yuan ($260 million) to buy a minority stake in Shenzhen Salubris Pharmaceutical Co., bringing its announced investment in health-care companies in Asia this year to almost $1 billion.

The U.S. fund will acquire a 5% stake in the biopharmaceutical company that sells finished drugs and medical devices, according to a Shenzhen stock exchange statement.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter